| 摘要 |
A method of inhibiting methotrexate sensitive leukemia L1210 and methotrexate resistant leukemias derived from L1210, such as variants L1210/FR-8, L1210/M-46-R, L1210/C-95, and L1210/M-66-3A in mice. This method produces optimum results as to the resistant leukemias as well as significant activity as to the sensitive leukemia. The compound employed is 5-methyltetrahydrohomofolate utilized as an injectable in a dosage regiment of 12.5-1600 mg/kg/inj/diem. The mechanism of action prefers dosages for at least two to four days, and in mice optimum results are obtained when treatment is commenced on day 1 following leukemia innoculation and is continued to the death of mice. |
